Opportunities to Optimize Cancer Policies Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Oct

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Prior Authorization Is Burdensome for Patients, Resulting in Treatment Delays, Financial Strain, and Stress

Antidepressants May Improve Surgical Outcomes in Patients With GI Cancer and Depression

Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas

Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer

Financial Toxicity Tied to Increased Risk of Mortality Among Patients With Cancer